Author

Yehia Elgammal

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Iturin A disrupts Cryptococcus neoformans membrane integrity, attenuates virulence, and synergizes with amphotericin B

Cryptococcus neoformans is a major fungal pathogen with severely limited therapeutic options. We evaluated the antifungal activity of the lipopeptide iturin A against eight clinical isolates of C. neoformans. Iturin A exhibited robust anti-cryptococcal activity, with minimum inhibitory concentrations ranging from 12.5...

Yehia Elgammal, Rafael García-Martínez, C. Charles-Niño et al. · npj Fungal Science · 0 citations

Open access Oct 2026

Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris

Candida auris is an emerging multidrug-resistant fungal pathogen and a major global health threat, highlighting the urgent need for new therapeutics. We screened ~2,600 FDA-approved drugs and clinical compounds and identified darapladib (DAL), a phospholipase A2 inhibitor, as a potent antifungal agent against multidrug...

Yehia Elgammal, Ehab A. Salama, Nour M. Alkashef et al. · PLoS ONE · 0 citations

Review Sep 2026

The skin as a reservoir for Candidozyma auris: colonization dynamics, host defense, and decolonization challenges

Abstract Candidozyma auris has emerged as one of the most formidable fungal pathogens of the modern era, designated a critical priority pathogen by the World Health Organization due to its multidrug resistance, thermotolerance, and capacity to cause prolonged outbreaks in healthcare settings. Unlike most fungal pathoge...

Débora Silva Marques de Sousa, Ana Karla Lima Freire Cabral, Bruno Bulgarelli Adorno Arantes et al. · Critical reviews in microbio... · 0 citations